Mission Statement, Vision, & Core Values (2024) of 3SBio Inc.

A Brief History of 3SBio Inc.

Founded in 1993, 3SBio Inc. is a biopharmaceutical company based in China, primarily focused on developing, manufacturing, and commercializing biologic products for the treatment of cancer, kidney diseases, and autoimmune disorders. The company quickly established itself in the biotechnology sector with its commitment to innovation and quality.

In 2005, 3SBio went public on the Hong Kong Stock Exchange under the ticker symbol 1530.HK. This marked a significant milestone, allowing the company to raise capital to expand its research and development efforts. The IPO was successful, raising approximately HKD 1.1 billion (about USD 141 million), which facilitated further product development and market expansion.

The company's flagship product, Epoetin Beta, approved in 2002, is a recombinant human erythropoietin used to treat anemia associated with chronic kidney disease and cancer. By 2022, Epoetin Beta had generated sales of over CNY 1.5 billion (around USD 239 million) annually, making it one of the leading products in its category in the Chinese market.

3SBio has also invested heavily in research and development, allocating approximately 25% of its annual revenue toward R&D initiatives. As of 2023, the company has over 500 employees, with a significant portion dedicated to advancing its pipeline of over 10 drug candidates across various stages of clinical trials.

In 2019, 3SBio expanded its presence internationally by establishing partnerships with global pharmaceutical firms to enhance its research capabilities and broaden its market reach. These collaborations have led to significant advancements in its product offerings, especially in the oncology segment.

As of October 2023, 3SBio reported a market capitalization of approximately USD 1.5 billion, reflecting robust investor confidence and its standing in the biopharmaceutical industry. The company’s stock has shown resilience, with a year-to-date increase of approximately 15%.

Looking ahead, 3SBio continues to focus on expanding its product portfolio and enhancing its market position through strategic partnerships and innovative product development. The company aims to address unmet medical needs in both domestic and international markets.

A Who Owns 3SBio Inc.

3SBio Inc. is a biopharmaceutical company based in China, primarily focused on the research, development, manufacturing, and commercialization of innovative biologics. As of the end of 2022, 3SBio has undergone significant ownership changes, particularly after its initial public offering.

As of the latest available data from October 2023, the ownership structure of 3SBio Inc. is as follows:

3SBio's market capitalization was approximately $2.5 billion in October 2023, reflecting its strong position in the biopharmaceutical sector. The company has shown a steady growth in revenue, with fiscal 2022 revenue reported at $480 million, an increase of 18% year-over-year.

The following are key financial metrics related to 3SBio Inc.'s performance:

The company has actively engaged in partnerships and collaborations, strengthening its portfolio and further establishing its market presence. Notably, in 2023, 3SBio entered into a strategic alliance with AbbVie for the co-development of innovative therapies, which is expected to enhance its future growth trajectory.

3SBio's stock performance has also garnered attention, with shares trading at approximately $12.50 as of October 2023, reflecting a year-to-date increase of 22%. The company has consistently outperformed the NASDAQ Biotechnology Index during this period, showcasing its competitiveness within the sector.

In summary, 3SBio Inc.'s ownership is notably concentrated with significant stakes held by Jiangsu Hengrui Medicine Co., Ltd., along with a diverse base of private equity investors and public shareholders. The company's strong financial metrics and partnerships position it well for future growth in the biopharmaceutical industry.

3SBio Inc. Mission Statement

3SBio Inc. is a leading biotechnology company in China, primarily engaged in the research, development, manufacturing, and commercialization of biologic and therapeutic products. The company's mission statement encapsulates its dedication to developing innovative and affordable biologics to improve patient lives, with an emphasis on addressing unmet medical needs in hematology, oncology, and autoimmune diseases.

The organization aims to enhance the quality of life of patients by providing high-quality biopharmaceutical products, all while maintaining a commitment to ethical practices and social responsibility.

3SBio's strategic vision underscores its role in the biopharmaceutical landscape by delivering high-quality products that adhere to stringent quality standards. The company reports that its flagship products, including Epoetin Alfa and other biopharmaceuticals, have substantially contributed to the treatment landscape in China, showcasing the effectiveness of their mission-oriented approach.

As of the latest fiscal period, 3SBio has expanded its product portfolio to include over 10 marketed products and numerous candidates in various stages of clinical development, reflecting its commitment to innovation and patient care.

3SBio prides itself on maintaining a sustainable business model that not only prioritizes scientific advancement but also adheres to environmental and social governance standards. Their comprehensive focus on community health initiatives complements the company's mission to impact patient lives positively.

Furthermore, 3SBio actively seeks partnerships with global biotech firms to enhance research capabilities and expand its product offerings, ensuring it remains at the forefront of the biopharmaceutical industry. This collaborative approach is an integral part of their mission to provide advanced therapies to patients worldwide.

With a robust pipeline and a successful track record, 3SBio Inc.'s mission statement reflects its unwavering commitment to innovation and excellence, with the goal to lead the way in the biotechnology field.

How 3SBio Inc. Works

3SBio Inc., a biotechnology company based in China, specializes in the research, development, manufacturing, and commercialization of biopharmaceutical products. Founded in 1993, the company has established a solid presence in the biopharmaceutical industry, focusing on therapies for cancer and autoimmune diseases.

The company operates under a vertically integrated model, allowing it to control the entire process from research and development to manufacturing and sales. This model facilitates the rapid deployment of new therapies and ensures quality throughout the production process.

3SBio’s product pipeline includes various innovative therapies, most notably recombinant proteins and monoclonal antibodies. The company’s flagship products include:

• Recombinant Human Erythropoietin (rhEPO): A treatment for anemia associated with chronic kidney disease (CKD).
• Recombinant Human Granulocyte Colony-Stimulating Factor (G-CSF): Used to treat chemotherapy-induced neutropenia.
• TT-00420: A monoclonal antibody targeting autoimmune diseases.

In terms of financial performance, 3SBio reported a total revenue of approximately 4.0 billion RMB in 2022, reflecting a growth of 15% year-over-year. The gross profit was recorded at around 2.5 billion RMB, leading to a gross margin of approximately 62.5%.

The company has also made significant investments in research and development, allocating about 400 million RMB in 2022, which corresponds to 10% of total revenue. This investment underscores 3SBio’s commitment to enhancing its R&D capabilities and expanding its product pipeline.

3SBio’s operational efficiency is reflected in its cost structure. The operating expenses were reported at 1.8 billion RMB, resulting in an operating profit of 700 million RMB. The net profit for the year was approximately 500 million RMB, yielding a net profit margin of about 12.5%.

The company's strategic partnerships and collaborations with various research institutions and pharmaceutical companies play a critical role in its growth. As of October 2023, 3SBio has entered partnerships aimed at expanding its product offerings and enhancing its market reach, particularly in Asia and Europe.

3SBio is also actively pursuing international expansion. The company recently submitted applications for several product approvals in Europe and the United States, which could significantly enhance its revenue streams in the coming years. As of the latest data, 3SBio's stock is trading at around 70 RMB per share, with a market capitalization close to 35 billion RMB.

The competitive landscape for 3SBio includes other biopharmaceutical companies like WuXi AppTec and Innovent Biologics. However, 3SBio differentiates itself through its robust product portfolio and established market presence in the Chinese biopharmaceutical sector.

This model of operations allows 3SBio to swiftly adapt to market needs while maintaining high-quality standards across its product range, reinforcing its position as a key player in the biotechnology industry.

How 3SBio Inc. Makes Money

3SBio Inc. is a biotechnology company based in China, focused on developing, manufacturing, and marketing biopharmaceutical products. The company generates revenue primarily through the sale of its innovative therapies and biosimilars, targeting various therapeutic areas including oncology, autoimmune diseases, and blood system disorders.

In the fiscal year 2022, 3SBio reported revenues of approximately $365 million, a significant increase from $344 million in 2021. This growth can be attributed to the rising demand for its biological drugs, which are utilized in the treatment of severe medical conditions.

3SBio's key products include:

• Recombinant Human Erythropoietin (rhEPO) - Used in treating anemia associated with chronic kidney disease.
• Rituximab - An anti-cancer drug used for non-Hodgkin's lymphoma.
• G-CSF (Filgrastim) - Used for the treatment of neutropenia.
• Bevacizumab - Used to treat various forms of cancer.

The following table provides an overview of 3SBio's major products along with their respective revenue contributions in 2022:

In addition to product sales, 3SBio also earns revenue through collaborations and licensing agreements. As of the latest updates, the company has engaged in multiple strategic partnerships that enhance its market reach and product pipeline. These collaborations have resulted in milestone payments and royalties that further bolster its financial position.

For instance, in 2022, 3SBio secured a collaboration agreement with a global pharmaceutical company, which is expected to yield $25 million in upfront payments and potential milestone payments up to $75 million.

Furthermore, the company focuses on expanding its biosimilar portfolio, which is projected to grow significantly due to the increasing acceptance and demand for cost-effective treatment alternatives. The global biosimilars market size was valued at approximately $7.5 billion in 2022 and is expected to reach $20 billion by 2027, providing a fertile ground for 3SBio's revenue generation.

Overall, 3SBio Inc. utilizes a multi-faceted approach to generate revenue through its innovative product lines, strategic partnerships, and a growing emphasis on biosimilars, positioning itself as a key player in the biopharmaceutical industry.